CN114929745B - Clec12a抗体片段序列和方法 - Google Patents

Clec12a抗体片段序列和方法

Info

Publication number
CN114929745B
CN114929745B CN202080087719.7A CN202080087719A CN114929745B CN 114929745 B CN114929745 B CN 114929745B CN 202080087719 A CN202080087719 A CN 202080087719A CN 114929745 B CN114929745 B CN 114929745B
Authority
CN
China
Prior art keywords
clec
seq
amino acid
cells
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080087719.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929745A (zh
Inventor
M·菲里西斯
J·S·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of CN114929745A publication Critical patent/CN114929745A/zh
Application granted granted Critical
Publication of CN114929745B publication Critical patent/CN114929745B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080087719.7A 2019-10-17 2020-10-14 Clec12a抗体片段序列和方法 Active CN114929745B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916340P 2019-10-17 2019-10-17
US62/916340 2019-10-17
PCT/US2020/055468 WO2021076545A1 (en) 2019-10-17 2020-10-14 Clec12a antibody fragment sequences and methods

Publications (2)

Publication Number Publication Date
CN114929745A CN114929745A (zh) 2022-08-19
CN114929745B true CN114929745B (zh) 2025-11-18

Family

ID=75538859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080087719.7A Active CN114929745B (zh) 2019-10-17 2020-10-14 Clec12a抗体片段序列和方法

Country Status (10)

Country Link
US (1) US20240117053A1 (https=)
EP (1) EP4045540A4 (https=)
JP (1) JP7796414B2 (https=)
KR (1) KR20220083760A (https=)
CN (1) CN114929745B (https=)
AU (1) AU2020368354A1 (https=)
BR (1) BR112022007219A2 (https=)
CA (1) CA3158111A1 (https=)
IL (1) IL292238A (https=)
WO (1) WO2021076545A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7512394B2 (ja) * 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
CN115850476B (zh) * 2022-08-09 2023-09-05 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018202649A1 (en) * 2017-05-02 2018-11-08 Alligator Bioscience Ab Bispecific antibody against ox40 and ctla-4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US20090215119A1 (en) * 2008-02-13 2009-08-27 Dyax Corp. Methods for producing specific binding pairs
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
HUE042040T2 (hu) * 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
CN103467599B (zh) * 2013-09-27 2015-06-17 中国农业科学院兰州兽医研究所 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
US11891426B2 (en) * 2017-12-15 2024-02-06 Aleta Biotherapeutics Inc. CD19 variants
MX2020007338A (es) * 2018-01-09 2020-11-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018202649A1 (en) * 2017-05-02 2018-11-08 Alligator Bioscience Ab Bispecific antibody against ox40 and ctla-4

Also Published As

Publication number Publication date
CA3158111A1 (en) 2021-04-22
IL292238A (en) 2022-06-01
JP7796414B2 (ja) 2026-01-09
CN114929745A (zh) 2022-08-19
EP4045540A1 (en) 2022-08-24
US20240117053A1 (en) 2024-04-11
WO2021076545A1 (en) 2021-04-22
JP2022553940A (ja) 2022-12-27
KR20220083760A (ko) 2022-06-20
BR112022007219A2 (pt) 2022-07-05
AU2020368354A1 (en) 2022-05-12
EP4045540A4 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
JP6738314B2 (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
US20240189423A1 (en) Bispecific binding agent-ligand fusions for the degradation of target proteins
JP2020096630A5 (https=)
WO2018177966A1 (en) Improved antigen binding receptors
TW200531979A (en) Inhibitors of type 2 vascular endothelial growth factor receptors
CN112912400B (zh) Nk接合子分子及其使用方法
US20230203166A1 (en) B7h3-targeting proteins and methods of use thereof
ES3036457T3 (en) A cd33-, cd16- and cd123-specific single chain triplebody
CN114929745B (zh) Clec12a抗体片段序列和方法
TW202305006A (zh) 與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體
JP2022512672A (ja) アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用
CN115023435B (zh) 免疫治疗化合物和方法
CN117964760B (zh) 抗人cll1/cd3的双特异性抗体及其应用
US20240317831A1 (en) Nk cell engager molecules and methods of use
US12269887B2 (en) Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
EP3385281A1 (en) Antibody to be cross-linked to human and mouse sema3a, and use thereof
CA3210650A1 (en) Bispecific antibodies enhancing cell mediated immune responses
CN115968378B (zh) 靶向b7h3的蛋白质及其使用方法
JP2026074003A (ja) Ｂ７ｈ３標的タンパク質及びその使用方法
WO2025136820A1 (en) Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use
HK40067100A (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
TH2001006532A (th) แอนติ-cd63 แอนติบอดี, คอนจูเกต และการใช้สิ่งเหล่านั้น

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant